HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab according to the data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA (Rigby et al., 2021). Here, HLA-DRB1 is linked to rheumatoid arthritis.